If We Pull the Plug on Drug Rebates, Can We Finally Focus on Value?

Posted by Pratap Khedkar on Thu, Oct 18, 2018

 

As more healthcare stakeholders clamor for price transparency, prescription drug rebates’ days could be numbered. Whether the behind-the-scenes negotiation tool—which has been linked to a growing discrepancy between a drug’s list and net prices—will partially or completely disappear is up for debate, but one certainty at this point is that the price transparency knock rarely goes unanswered.


>
Read More

Trump’s Drug Pricing Plan: What Does it Really Mean for Pharma?

Posted by Pratap Khedkar on Thu, May 17, 2018

Howard Deutsch co-authored this blog post with Pratap Khedkar.

President Donald Trump and HHS Secretary Alex Azar addressed the nation from the White House Rose Garden last week, introducing American Patients First, a drug pricing plan that Pres. Trump described as the “most sweeping action in history to lower the price of prescription drugs.” Let’s take a closer look, shall we?


>
Read More